NCT00383149 - A Phase II, Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

June 30, 2009

Study Completion Date

June 30, 2009

Conditions

Metastatic Pancreatic Cancer

Interventions

DRUG

Ixabepilone

Intravenous Infusion (IV), 32 mg/m\^2 every 21 days.

DRUG

Cetuximab

Initial dose of 400 mg/m\^2 intravenous (IV) over 2 hours) followed by a weekly lower dose of 250 mg/m\^2 IV over 1 hour.

Trial Locations (9)

Georgetn Univ Lombardi Can Ctr, Washington D.C.

West Virginia University, Morgantown

Cancer Centers Of The Carolinas, Greenville

Mayo Clinic Jacksonville, Jacksonville

University Of Miami, Miami

University Of Michigan, Ann Arbor

Wayne State University, Detroit

Ellis Fischel Cancer Center, Columbia

Seattle Cancer Care Alliance, Seattle